JP2018184417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018184417A5 JP2018184417A5 JP2018126675A JP2018126675A JP2018184417A5 JP 2018184417 A5 JP2018184417 A5 JP 2018184417A5 JP 2018126675 A JP2018126675 A JP 2018126675A JP 2018126675 A JP2018126675 A JP 2018126675A JP 2018184417 A5 JP2018184417 A5 JP 2018184417A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- amino acid
- acid sequence
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- -1 4-((2- (4-chlorophenyl) -4,4-dimethylcyclohex-1-enyl) methyl) piperazin-1-yl Chemical group 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698379P | 2012-09-07 | 2012-09-07 | |
| US61/698,379 | 2012-09-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531246A Division JP6408993B2 (ja) | 2012-09-07 | 2013-09-06 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019227891A Division JP2020063279A (ja) | 2012-09-07 | 2019-12-18 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018184417A JP2018184417A (ja) | 2018-11-22 |
| JP2018184417A5 true JP2018184417A5 (OSRAM) | 2019-06-20 |
| JP6637119B2 JP6637119B2 (ja) | 2020-01-29 |
Family
ID=49253396
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531246A Active JP6408993B2 (ja) | 2012-09-07 | 2013-09-06 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
| JP2018126675A Active JP6637119B2 (ja) | 2012-09-07 | 2018-07-03 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
| JP2019227891A Pending JP2020063279A (ja) | 2012-09-07 | 2019-12-18 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
| JP2022064357A Pending JP2022091996A (ja) | 2012-09-07 | 2022-04-08 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ－２インヒビターの併用療法 |
| JP2024063799A Pending JP2024095793A (ja) | 2012-09-07 | 2024-04-11 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ－２インヒビターの併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531246A Active JP6408993B2 (ja) | 2012-09-07 | 2013-09-06 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019227891A Pending JP2020063279A (ja) | 2012-09-07 | 2019-12-18 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
| JP2022064357A Pending JP2022091996A (ja) | 2012-09-07 | 2022-04-08 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ－２インヒビターの併用療法 |
| JP2024063799A Pending JP2024095793A (ja) | 2012-09-07 | 2024-04-11 | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ－２インヒビターの併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (14) | US9539251B2 (OSRAM) |
| EP (2) | EP2892557A1 (OSRAM) |
| JP (5) | JP6408993B2 (OSRAM) |
| KR (2) | KR20200110711A (OSRAM) |
| CN (3) | CN111481552A (OSRAM) |
| CA (1) | CA2884307A1 (OSRAM) |
| HK (1) | HK1212240A1 (OSRAM) |
| MX (1) | MX2015002947A (OSRAM) |
| NZ (1) | NZ630166A (OSRAM) |
| RU (1) | RU2648476C2 (OSRAM) |
| WO (1) | WO2014039855A1 (OSRAM) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0416262B1 (pt) | 2003-11-05 | 2022-04-12 | Roche Glycart Ag | Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica |
| EP2641618A3 (en) | 2007-07-16 | 2013-10-23 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
| CL2008002085A1 (es) | 2007-07-16 | 2008-11-21 | Genentech Inc | Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b |
| CN104650230A (zh) | 2008-01-31 | 2015-05-27 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2014018567A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| CN111481552A (zh) * | 2012-09-07 | 2020-08-04 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
| BR112015025711A8 (pt) * | 2013-04-08 | 2019-12-17 | Janssen Pharmaceutica Nv | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer |
| WO2015095410A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| AU2015249554B2 (en) | 2014-04-23 | 2021-08-19 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| LT3179991T (lt) * | 2014-08-11 | 2021-11-10 | Acerta Pharma B.V. | Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai |
| EP3262071B8 (en) | 2014-09-23 | 2022-05-18 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| IL302486A (en) | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Antibodies against the transnephrine receptor with adapted affinity |
| EP3313885A1 (en) * | 2015-06-29 | 2018-05-02 | H. Hoffnabb-La Roche Ag | Type ii anti-cd20 antibody for use in organ transplantation |
| LT3319995T (lt) * | 2015-07-07 | 2019-07-10 | F. Hoffmann-La Roche Ag | Sudėtinis gydymas anti-her-2 antikūno-vaisto konjugatu ir bcl-2 inhibitoriumi |
| TW201717953A (zh) * | 2015-08-03 | 2017-06-01 | 基利科學股份有限公司 | 用於治療癌症之組合療法 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| CN114057885A (zh) | 2015-10-02 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
| WO2017079399A1 (en) | 2015-11-03 | 2017-05-11 | Genentech, Inc. | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer |
| CN107384932B (zh) | 2016-08-31 | 2020-10-20 | 北京天广实生物技术股份有限公司 | 抗人cd20人源化单克隆抗体mil62、其制备方法及用途 |
| WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| US11554127B2 (en) * | 2018-07-31 | 2023-01-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| CA3095699A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CN112955172A (zh) | 2018-09-17 | 2021-06-11 | 美国卫生和人力服务部 | 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途 |
| SG11202103235PA (en) * | 2018-10-01 | 2021-04-29 | Adicet Bio Inc | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS |
| US20210401859A1 (en) | 2018-11-01 | 2021-12-30 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| MX2022004766A (es) | 2019-10-21 | 2022-05-16 | Novartis Ag | Terapias combinadas con venetoclax e inhibidores de tim-3. |
| TW202128191A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | Tim-3抑制劑及其用途 |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| CN116635062A (zh) | 2020-11-13 | 2023-08-22 | 诺华股份有限公司 | 使用表达嵌合抗原受体（car）的细胞的组合疗法 |
| CN117529505A (zh) | 2021-03-24 | 2024-02-06 | 美国卫生和人力服务部 | 设计为减少逆转录病毒重组的双顺反子嵌合抗原受体及其用途 |
| WO2022216942A1 (en) | 2021-04-07 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| CN117241802A (zh) * | 2021-04-21 | 2023-12-15 | 新基公司 | 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法 |
| TW202243689A (zh) | 2021-04-30 | 2022-11-16 | 瑞士商赫孚孟拉羅股份公司 | 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥 |
| JP2025526003A (ja) * | 2022-08-09 | 2025-08-07 | 康百達（四川）生物医薬科技有限公司 | ピペラジン化合物とｐｄ－１阻害剤またはｐｄ－ｌ１阻害剤との組成物、および腫瘍治療におけるその使用 |
| AU2024230609A1 (en) | 2023-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Cell therapy for treating systemic autoimmune diseases |
| TW202533828A (zh) * | 2024-02-22 | 2025-09-01 | 瑞典商阿斯特捷利康公司 | Ａｋｔ抑制劑、ｂｃｌ－２抑制劑、及抗ｃｄ２０抗體之治療組合 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| HK1040720A1 (zh) | 1998-05-15 | 2002-06-21 | 伊姆克罗尼系统公司 | 用辐射和生长因子受体酪氨酸激酶抑制剂治疗人肿瘤 |
| EP1498485A4 (en) | 2002-04-09 | 2006-09-06 | Kyowa Hakko Kogyo Kk | MODIFIED GENOME CELLS |
| KR100932340B1 (ko) | 2002-10-17 | 2009-12-16 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| BRPI0416262B1 (pt) * | 2003-11-05 | 2022-04-12 | Roche Glycart Ag | Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| JP5277168B2 (ja) | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| BR122019016429B1 (pt) | 2009-05-26 | 2020-03-24 | Abbvie Ireland Unlimited Company | Compostos inibidores da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo ditos compostos |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2011100403A1 (en) * | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| ES2699205T3 (es) | 2010-10-29 | 2019-02-07 | Abbvie Inc | Dispersiones sólidas que contienen un agente que induce la apoptosis |
| NZ708508A (en) | 2010-11-23 | 2016-06-24 | Abbvie Bahamas Ltd | Methods of treatment using selective bcl-2 inhibitors |
| AU2011332043C1 (en) | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| CN111481552A (zh) | 2012-09-07 | 2020-08-04 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
| AR095265A1 (es) | 2013-03-13 | 2015-09-30 | Abbvie Inc | Procesos para la preparación de un agente inductor de la apoptosis |
| CN107847600B (zh) | 2015-05-26 | 2021-09-03 | 豪夫迈·罗氏有限公司 | 抗CD20抗体与Bcl-2抑制剂和MDM2抑制剂的组合疗法 |
| WO2017079399A1 (en) * | 2015-11-03 | 2017-05-11 | Genentech, Inc. | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer |
-
2013
- 2013-09-06 CN CN202010088180.9A patent/CN111481552A/zh active Pending
- 2013-09-06 CN CN202010088179.6A patent/CN111437386A/zh active Pending
- 2013-09-06 US US14/020,761 patent/US9539251B2/en active Active
- 2013-09-06 JP JP2015531246A patent/JP6408993B2/ja active Active
- 2013-09-06 CA CA2884307A patent/CA2884307A1/en active Pending
- 2013-09-06 EP EP13767170.7A patent/EP2892557A1/en not_active Withdrawn
- 2013-09-06 HK HK16100331.0A patent/HK1212240A1/xx unknown
- 2013-09-06 NZ NZ630166A patent/NZ630166A/en unknown
- 2013-09-06 MX MX2015002947A patent/MX2015002947A/es active IP Right Grant
- 2013-09-06 RU RU2015112576A patent/RU2648476C2/ru active
- 2013-09-06 KR KR1020207026653A patent/KR20200110711A/ko active Pending
- 2013-09-06 EP EP21173041.1A patent/EP3919079A1/en active Pending
- 2013-09-06 KR KR1020157008862A patent/KR102158467B1/ko active Active
- 2013-09-06 WO PCT/US2013/058557 patent/WO2014039855A1/en not_active Ceased
- 2013-09-06 CN CN201380057990.6A patent/CN104768581A/zh active Pending
-
2016
- 2016-11-30 US US15/365,595 patent/US11413282B2/en active Active
-
2018
- 2018-07-03 JP JP2018126675A patent/JP6637119B2/ja active Active
-
2019
- 2019-12-18 JP JP2019227891A patent/JP2020063279A/ja active Pending
-
2020
- 2020-03-23 US US16/827,650 patent/US10993942B2/en active Active
-
2021
- 2021-02-26 US US17/187,468 patent/US11110087B2/en active Active
- 2021-03-05 US US17/193,795 patent/US20220008413A1/en not_active Abandoned
- 2021-08-05 US US17/395,366 patent/US20220211696A1/en not_active Abandoned
-
2022
- 2022-03-30 US US17/709,324 patent/US20220265642A1/en not_active Abandoned
- 2022-04-08 JP JP2022064357A patent/JP2022091996A/ja active Pending
- 2022-06-07 US US17/834,709 patent/US11590128B2/en active Active
-
2023
- 2023-01-20 US US18/157,680 patent/US20230226045A1/en not_active Abandoned
- 2023-03-28 US US18/191,810 patent/US20230255959A1/en not_active Abandoned
- 2023-09-07 US US18/463,252 patent/US20240000776A1/en not_active Abandoned
- 2023-11-10 US US18/506,606 patent/US20240108616A1/en not_active Abandoned
- 2023-12-08 US US18/534,251 patent/US20240180901A1/en not_active Abandoned
-
2024
- 2024-04-11 JP JP2024063799A patent/JP2024095793A/ja active Pending
-
2025
- 2025-01-17 US US19/030,370 patent/US20250152582A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018184417A5 (OSRAM) | ||
| JP2015529225A5 (OSRAM) | ||
| RU2015112576A (ru) | Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2 | |
| JP2020503260A5 (OSRAM) | ||
| JP2017501157A5 (OSRAM) | ||
| JP2020518599A5 (OSRAM) | ||
| JP2018108086A5 (OSRAM) | ||
| JP2017507954A5 (OSRAM) | ||
| JP2018506550A5 (OSRAM) | ||
| JP2012036225A5 (OSRAM) | ||
| JP2017514795A5 (OSRAM) | ||
| RU2756405C2 (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| JP2009518441A5 (OSRAM) | ||
| JP2011506483A5 (OSRAM) | ||
| JP2017537105A5 (OSRAM) | ||
| JP2017160178A5 (OSRAM) | ||
| JP2008510714A5 (OSRAM) | ||
| IL263110B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| JP2019517549A5 (OSRAM) | ||
| JP2015505564A5 (OSRAM) | ||
| JP2015500822A5 (OSRAM) | ||
| JP2015172060A5 (OSRAM) | ||
| JP2019524820A5 (OSRAM) | ||
| JP2019534003A5 (OSRAM) | ||
| JP2019534251A5 (OSRAM) |